EyePoint's Experimental Eye Disease Treatment Misses Main Goal in Late-Stage Trial

What's Happening

EyePoint Pharmaceuticals announced that its experimental treatment Duravyu failed to meet the primary goal of a Phase 3 clinical trial for wet age-related macular degeneration (AMD), sending the company's shares down more than 70%.

The trial compared Duravyu with Regeneron's Eylea, the current standard treatment for wet AMD. Although Duravyu significantly reduced the number of eye injections patients needed, it did not demonstrate that it preserved vision as effectively as Eylea across the full study population.

Understanding Wet Age-Related Macular Degeneration

Wet AMD is a leading cause of vision loss in adults over 50. The disease occurs when abnormal blood vessels grow beneath the retina and leak fluid or blood, damaging central vision. Current treatments typically require frequent injections into the eye, often every one to two months, creating a significant treatment burden for patients. Duravyu was designed as a long-acting therapy capable of maintaining vision while reducing the number of injections required.

Why the Trial Missed Its Goal

The Phase 3 study evaluated whether Duravyu was non-inferior to Eylea in preserving patients' vision after one year of treatment. The trial failed its primary endpoint because nine patients receiving Duravyu experienced significant vision loss unrelated to their wet AMD, while no comparable events occurred in the Eylea group. These unexpected cases affected the overall statistical results.

EyePoint said that when those nine unrelated cases were excluded in a post-hoc analysis, Duravyu met the non-inferiority target while continuing to reduce treatment burden by approximately 42% compared with Eylea. However, regulators generally place greater weight on the predefined primary analysis.

Industry Impact

• Patients: Duravyu's longer-lasting treatment approach could still offer meaningful benefits if future studies confirm its effectiveness, potentially reducing the frequency of eye injections.
• Healthcare Providers: Retina specialists will continue relying primarily on existing anti-VEGF therapies while awaiting results from EyePoint's second Phase 3 trial.
• Biotechnology Industry: The setback highlights the challenges of developing treatments that must match the effectiveness of well-established therapies such as Eylea while also improving convenience.
• Investors: The disappointing results erased more than $900 million in EyePoint's market value as investors questioned the therapy's regulatory prospects.

Looking Ahead

EyePoint plans to continue development and expects results from its second Phase 3 study, Lucia, later this year. The company intends to seek FDA approval in the first half of 2027 if the second trial is successful, arguing that previous FDA approvals have occasionally been supported by one positive pivotal study combined with additional clinical evidence. Analysts, however, believe obtaining approval without two successful pivotal trials could be difficult.

Why This Matters

Wet age-related macular degeneration affects millions of older adults and often requires lifelong treatment. A therapy that safely reduces injection frequency could significantly improve quality of life and reduce the burden on patients and retina specialists. While Duravyu showed promise in lowering treatment frequency, the trial outcome illustrates the high evidentiary standards required for approval of new ophthalmology therapies.

Key Takeaways

• EyePoint's Phase 3 trial for Duravyu missed its primary endpoint in wet AMD.
• The company's shares fell more than 70% following the announcement.
• Nine unexpected vision-loss cases unrelated to wet AMD contributed to the failed primary analysis.
• Duravyu reduced treatment burden by about 42% compared with Eylea.
• EyePoint will continue with a second Phase 3 trial and still plans to pursue FDA approval if those results are positive.

What This Means for Healthcare Marketers

The trial highlights the continued demand for innovations that improve treatment durability in ophthalmology while maintaining clinical effectiveness. Pharmaceutical companies, retina specialists, ophthalmology practices, and medical device developers continue investing in therapies that reduce treatment burden for chronic eye diseases. For healthcare marketers, organizations involved in ophthalmology, retinal diseases, biotechnology, and clinical development represent high-intent opportunities for physician education, scientific communications, clinical trial awareness, and commercialization planning.